An Asia Pacific Non-Randomized, Open-Label Phase II Study Evaluating the Safety and Efficacy of FOLFIRI Plus Cetuximab (Erbitux) or FOLFOX Plus Cetuximab as First-Line Therapy in Subjects With KRAS Wild-Type Metastatic Colorectal Cancer (APEC-Study).

Trial Profile

An Asia Pacific Non-Randomized, Open-Label Phase II Study Evaluating the Safety and Efficacy of FOLFIRI Plus Cetuximab (Erbitux) or FOLFOX Plus Cetuximab as First-Line Therapy in Subjects With KRAS Wild-Type Metastatic Colorectal Cancer (APEC-Study).

Completed
Phase of Trial: Phase II

Latest Information Update: 24 Aug 2016

At a glance

  • Drugs Cetuximab (Primary) ; Fluorouracil; Folinic acid; Irinotecan; Oxaliplatin
  • Indications Colorectal cancer
  • Focus Therapeutic Use
  • Acronyms APEC
  • Sponsors Merck KGaA
  • Most Recent Events

    • 05 Jun 2014 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov record.
    • 30 Jan 2012 Actual patient number changed from 287 to 288 as reported by ClinicalTrials.gov.
    • 23 Nov 2010 Planned End Date changed from 1 Sep 2012 to 1 Jun 2013.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top